Immuno oncology News and Research

RSS

Quanterix announces $50,000 in grants to support promising oncology research

Quanterix announced a call for proposals for a new Accelerator Grant Program.

From Quanterix 16 May 2019

7th Annual PREDiCT: Tumor Models Boston summit will help scientists to improve cancer research

The 7th Annual PREDiCT: Tumor Models Boston summit will be held on July 16 – 18 2019 in Boston, MA. For its anticipated return, Tumor Models Boston rebrands alongside its sister events in San Francisco, London and Asia to become PREDiCT: Tumor Models Boston as part of the PREDiCT: Tumor Models Series.

From PREDiCT 24 Apr 2019

New class of drugs could help treat patients diagnosed with ovarian cancer

A team of researchers across The University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

19 Mar 2019

New analysis highlights increasing focus of early-stage clinical trials on rare cancers

The proportion of early-stage drug trials tackling the biggest cancer killers has declined sharply since the early 1990s as less common tumor types receive increasing attention, according to new research to be presented during the International Congress on Targeted Anticancer Therapies 2019, taking place from today to 27 February in Paris, France.

25 Feb 2019

Immune checkpoint molecule protects against future development of cancer

A research team at the University of Louisville has discovered that an immune checkpoint molecule they developed for cancer immunotherapy, also protects against future development of multiple types of cancer when administered by itself.

15 Feb 2019

MD Anderson Cancer Center collaborates with Dragonfly for new immunotherapy drug clinical trials

The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly's TriNKET™ immunotherapy drug candidates to patients in clinical trials beginning in 2019.

16 Jan 2019

Quanterix extends oncology footprint with accelerated launch of next gen SP-X platform and CorPlex validated 10-Plex

Quanterix announce launch of its Simoa SP-X Imaging and Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu of additional multiplex panels.

From Quanterix 10 Jan 2019

MD Anderson Cancer Center and Nanobiotix collaborate to expand clinical development of NBTXR3

The University of Texas MD Anderson Cancer Center and Nanobiotix today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers, with the first trials to be launched in 2019.

7 Jan 2019

Cytek marks major milestone by shipping its 100th advanced flow cytometry system

Cytek Biosciences Inc., the preeminent provider of innovative flow cytometry solutions, has marked a significant milestone: the company has shipped 100 of its advanced flow cytometry systems.

From Cytek Biosciences 7 Jan 2019

MD Anderson Cancer Center and 4D pharma team up to evaluate live biotherapeutic oncology pipeline

The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D's live biotherapeutic oncology pipeline across a range of cancer settings.

7 Jan 2019

Personalization techniques give a new lease of life to anticancer vaccines

Anticancer vaccines have gained a new lease of life with techniques to personalise them to individual patients.

19 Dec 2018

The EORTC Brain Tumor Group and Protagen AG collaborate to study immuno-competence of long-term glioblastoma survivors

The European Organisation for Research and Treatment of Cancer Brain Tumor Group and Protagen AG today announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify autoantibody biomarkers that investigate the immunological profile and immuno-competence of long-term Glioblastoma survivors.

12 Dec 2018

Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics

Integral Molecular, the industry leader in the discovery of monoclonal antibodies against membrane proteins, and Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that they have entered into a collaboration on multiple undisclosed targets.

12 Dec 2018

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse array of topics to be discussed at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland.

11 Dec 2018

Customizing Genetically Engineered Models for Specific Research Applications

In this interview conducted at SfN 2018, Philip Dubé from Taconic Biosciences, goes into detail about genetically engineered models and their importance in understanding neurodegenerative diseases.

From Taconic Biosciences, Inc. 4 Dec 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.

From AMGEN 5 Nov 2018

Cytek Biosciences introduces new Northern Lights series of advanced flow cytometry systems

The door to discovery has been opened, and the traditional flow cytometry market is set to see a paradigm shift. With its new Northern Lights series of advanced flow cytometry systems, Cytek Biosciences Inc. is making three lasers and more than 24 colors possible at a price point typically attached to systems with far fewer capabilities.

From Cytek Biosciences 2 Nov 2018

Integral Molecular wins NIH grant to initiate target discovery program for Alzheimer’s disease

Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research grant from the NIH to initiate a target discovery program for Alzheimer's disease.

1 Nov 2018

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

Researchers from City of Hope, a world-renowned comprehensive cancer center and independent biomedical research institution, have developed a synthetic DNA molecule that is programmed to jump-start the immune system to eradicate genetically distinct types of prostate cancer.

19 Oct 2018

LJI and UC San Diego awarded $ 4.5 million as part of NCI's Cancer Moonshot initiative

Researchers at La Jolla Institute for Immunology and UC San Diego have been awarded $ 4.5 million as part of the National Cancer Institute's Cancer Moonshot initiative.